The Oncomine Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI) Test is a comprehensive diagnostic tool offered by DNA Labs UAE, designed to assess two critical biomarkers in cancer patients: Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI). This test is pivotal in the realm of precision medicine, as it helps in identifying the genetic alterations within tumors, thereby guiding oncologists in tailoring the most effective treatment strategies for individual patients.
TMB is a measure of the number of mutations within a tumor's DNA, which can be indicative of how well a patient might respond to certain immunotherapies. A high TMB can suggest a tumor is more likely to respond to these treatments. On the other hand, MSI is a condition that occurs due to the failure of the DNA mismatch repair system, leading to increased mutations. It is particularly prevalent in certain types of cancers, such as colorectal cancer, and its presence can also influence treatment decisions, including the use of immunotherapy.
The test is conducted through a sophisticated genomic sequencing process, analyzing a comprehensive panel of genes associated with various cancers to determine the TMB and MSI status. The cost of the test at DNA Labs UAE is 10,500 AED, reflecting the advanced technology and expertise required to perform this intricate analysis. By providing a detailed genetic profile of a patient's tumor, the Oncomine TMB and MSI Test plays a crucial role in advancing personalized cancer care, offering hope for more effective and targeted treatment options.
The Wilson Disease ATP7B Gene Mutation Detection Test is a specialized diagnostic procedure aimed at identifying mutations in the ATP7B gene, which are responsible for Wilson Disease. Wilson Disease is a rare genetic disorder that leads to excessive accumulation of copper in the body, affecting the liver, brain, and other vital organs. Early detection and treatment are crucial for managing the disease effectively.
This test is conducted by DNA Labs UAE, a leading facility in genetic testing, ensuring high accuracy and reliability of results. By analyzing the patient's DNA, the test can pinpoint specific mutations in the ATP7B gene, confirming the diagnosis of Wilson Disease. This information is vital for clinicians to devise appropriate treatment plans and for affected families to understand the risk of inheritance.
The cost of the Wilson Disease ATP7B Gene Mutation Detection Test at DNA Labs UAE is 10,500 AED. Although the price may seem high, the test offers invaluable insights into managing and treating a potentially life-threatening condition, making it a critical investment in the health and well-being of individuals at risk for or suspected of having Wilson Disease.
Autoimmune Cerebellar Ataxia Panel Test is a specialized diagnostic examination designed to identify the presence of specific antibodies that may contribute to autoimmune cerebellar ataxia, a condition where the immune system mistakenly attacks the cerebellum, part of the brain that controls coordination and balance. This comprehensive panel aims to facilitate the accurate diagnosis of autoimmune-related cerebellar ataxia, distinguishing it from other types of ataxia caused by genetic factors, toxins, or other diseases. Conducted at DNA Labs UAE, a facility known for its advanced diagnostic technologies and expertise in genetic and autoimmune disorders, the test costs 11,790 AED. By pinpointing the exact antibodies causing the immune response, healthcare providers can tailor treatment plans more effectively, offering hope for improved management of symptoms and quality of life for affected individuals.
The Lung Cancer Panel 8 EGFRBRAFALKROSMETPDL1 Test is a comprehensive diagnostic tool designed to identify genetic mutations and markers associated with lung cancer. This advanced panel test targets specific genes such as EGFR, BRAF, ALK, ROS, MET, and the protein PD-L1, which are critical in the development, progression, and treatment response of lung cancer. By analyzing these genetic components, the test aids in the personalization of treatment plans, allowing for targeted therapies that can significantly improve patient outcomes.
Performed at DNA Labs UAE, a leading facility in genetic testing and analysis, this test represents a significant advancement in the field of oncology. The cost of the Lung Cancer Panel 8 Test is 8000 AED, reflecting the comprehensive nature of the analysis and the sophisticated technology employed. By providing detailed insights into the genetic underpinnings of an individual's lung cancer, the test supports more informed decision-making in treatment planning, potentially leading to more effective management of the disease.
The Oncomine Focus Panel Test, offered at DNA Labs UAE for a cost of 9000 AED, is a state-of-the-art genetic test designed to identify specific mutations in cancer cells. This targeted sequencing panel is utilized to analyze a select set of genes that are known to be involved in various types of cancers. By pinpointing these genetic alterations, the test aids oncologists in developing personalized treatment plans for patients, potentially improving outcomes and minimizing unnecessary treatments. DNA Labs UAE, equipped with advanced genomic technologies, ensures precise and reliable results, making the Oncomine Focus Panel Test a valuable tool in the field of precision oncology.
Pre-Implantation Genetic Diagnosis (PGD) for single gene disorders with a known mutation is a cutting-edge genetic testing procedure designed to identify genetic abnormalities in embryos before implantation. This test is particularly vital for couples who are at risk of passing on genetic disorders to their offspring. By pinpointing the specific mutation in an embryo, PGD allows for the selection of healthy embryos for implantation, significantly reducing the risk of having a child affected by the genetic condition in question.
At DNA Labs UAE, this specialized test is offered at a cost of 9000 AED. The process involves collecting a small number of cells from embryos created through in vitro fertilization (IVF) and analyzing them for the presence of the known genetic mutation. This baseline test is crucial for couples who are carriers of or have a family history of genetic disorders, offering them a path to having biologically related children with significantly lowered genetic risks. DNA Labs UAE utilizes state-of-the-art technology and expertise to ensure accurate, reliable results, providing invaluable peace of mind and support to prospective parents navigating the complexities of genetic disorders.
The Comprehensive Tumor Panel 270 Genes and PD-L1 Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to provide a detailed genetic profile of tumors. Priced at 9000 AED, this test analyzes 270 genes associated with various cancers, offering insights into the genetic alterations and mutations that could be driving the growth and spread of cancer cells. Additionally, it includes an assessment for PD-L1, a protein that plays a critical role in the body's immune response to cancer. By evaluating the presence and expression level of PD-L1, this test can help in identifying patients who are likely to benefit from immunotherapy treatments. This comprehensive approach not only aids in the accurate diagnosis and understanding of an individual’s cancer but also guides personalized treatment strategies, enhancing the potential for successful outcomes.
The Oncopro PD-L1 Circulating Tumor Cells Test is a cutting-edge diagnostic tool available at DNA Labs UAE, designed to detect and quantify circulating tumor cells (CTCs) that express the PD-L1 protein in a patient's bloodstream. This test is particularly valuable for patients with various types of cancer, as the presence and level of PD-L1 expression on CTCs can provide critical information regarding the tumor's biology, potential aggressiveness, and possible response to certain immunotherapy treatments.
By isolating and analyzing CTCs, the Oncopro PD-L1 test offers a non-invasive alternative to traditional biopsy methods, allowing for the monitoring of cancer progression and response to treatment over time without the need for surgical procedures. This can be especially beneficial for patients with tumors that are difficult to access or for those in whom multiple biopsies are risky or not feasible.
The test cost is set at 9880 AED, reflecting the sophisticated technology and expertise required to accurately identify and quantify PD-L1 expressing CTCs. Conducted at DNA Labs UAE, a facility known for its advanced diagnostic services and commitment to precision medicine, the Oncopro PD-L1 Circulating Tumor Cells Test represents a significant advancement in the personalized treatment of cancer, offering hope for more targeted and effective therapies based on the unique characteristics of each patient's disease.
The NGS Homologous Recombinant Deficiency (HRD) Panel Test is a cutting-edge genetic testing procedure conducted at DNA Labs UAE, designed to assess the efficiency of DNA repair mechanisms in cells, particularly focusing on the homologous recombination repair (HRR) pathway. This test is pivotal in the realm of personalized medicine, especially for patients with cancer, as defects in the HRR pathway are associated with increased sensitivity to certain chemotherapeutic agents and PARP inhibitors.
Utilizing Next-Generation Sequencing (NGS) technology, this panel test comprehensively scans for mutations in genes involved in the HRR pathway, such as BRCA1, BRCA2, and others, which are crucial for accurate DNA repair. Identifying deficiencies in homologous recombination can help predict the response to specific cancer therapies, enabling healthcare providers to tailor treatment plans to the genetic profile of the patient's tumor, thereby enhancing treatment efficacy and potentially improving patient outcomes.
The test cost is set at 10530 AED, reflecting the sophisticated technology and expertise required to perform this advanced genetic analysis. Conducted at DNA Labs UAE, a facility known for its state-of-the-art genetic testing services, the NGS HRD Panel Test represents a significant advancement in the field of oncology and personalized medicine, offering hope for more effective and customized cancer treatment strategies.
The Oncomine Tumor Mutation Burden (TMB) Test is a cutting-edge genomic profiling tool designed to evaluate the mutation burden within a tumor's DNA. This comprehensive assessment is performed at DNA Labs UAE, a leading facility in genomic and molecular diagnostics. The test specifically quantifies the number of mutations per megabase of DNA in a tumor sample, providing crucial insights that can guide personalized cancer treatment strategies.
With a cost of 8400 AED, the Oncomine TMB Test stands as a valuable investment for patients and healthcare providers seeking to optimize cancer therapy. By identifying the tumor mutation burden, this test can help predict response to certain immunotherapies, making it a key component in the management of various cancer types. The results from the Oncomine TMB Test enable clinicians to tailor treatment plans more effectively, potentially improving patient outcomes in the rapidly evolving field of oncology.
